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        Alzheimer  ’  s disease (AD) is the most common 
neurodegenerative disorder leading to dementia. 
Neuritic plaques, neurofi  brillary tangles, and 
neuronal loss represent the main histological 
hallmarks observed in AD brains. Amyloid     -
protein (A    ), the central component of senile 
plaques, is produced from sequential endopro-
teolytic cleavages of the type 1 transmembrane 
glycoprotein    -amyloid precursor protein (APP) 
by     - and     -secretase (  1  ).     -Site APP cleaving 
enzyme 1 (BACE1) is the     -secretase in vivo 
(  2  –  6  ).     -Secretase is an atypical multimeric 
membrane-protein aspartic protease composed 
of at least four subunits: presenilin (PS1 or PS2), 
nicastrin (Nct), APH-1 (APH-1aL, APH-1aS, 
or APH-1b), and PEN-2 (  7  –  11  ). More recently, 
two additional proteins, CD147 and TMP21, 
were found to be closely associated with the     -
secretase complex (  12, 13  ).The components 
of the     -secretase complex are tightly regulated 
with each other, and PS1 is generally believed to 
be its catalytic core (  14, 15  ). Another important 
substrate of     -secretase is Notch, whose intra-
cellular domain (NICD) is released upon     -
secretase cleavage and translocates to the nucleus, 
where it can activate transcription of down-
stream target genes (  8, 10  ). In addition to its role 
in Notch signaling and APP processing,     -secre-
tase is also involved in regulating intramembra-
neous proteolysis of many other type I integral 
membrane proteins, such as Jagged, Delta, E-
cadherin, ErbB-4, Nectin-1    , CD44, and LRP 
(  16  –  22  ). Missense mutations in the PS1 and PS2 
genes are major causes of early-onset familial 
AD (  23  –  25  ). Although the underlying mecha-
nism of AD neurodegeneration is currently un-
clear, A     accumulation appears to play a critical 
role in AD pathogenesis. 
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  Neuritic plaques in the brains are one of the pathological hallmarks of Alzheimer  ’  s disease 
(AD). Amyloid     -protein (A    ), the central component of neuritic plaques, is derived from 
    -amyloid precursor protein (APP) after     - and     -secretase cleavage. The molecular 
mechanism underlying the pathogenesis of AD is not yet well defi  ned, and there has been 
no effective treatment for AD. Valproic acid (VPA) is one of the most widely used anticon-
vulsant and mood-stabilizing agents for treating epilepsy and bipolar disorder. We found 
that VPA decreased A     production by inhibiting GSK-3      –  mediated     -secretase cleavage 
of APP both in vitro and in vivo. VPA treatment signifi  cantly reduced neuritic plaque for-
mation and improved memory defi  cits in transgenic AD model mice. We also found that 
early application of VPA was important for alleviating memory defi  cits of AD model mice. 
Our study suggests that VPA may be benefi  cial in the prevention and treatment of AD. 
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P   <   0.001, respectively; Fig. S2). APP23 mice were also treated 
with VPA at 9 mo of age. Signifi  cantly more neuritic plaques 
were formed in the mice at 9 mo compared with 7 mo of age; 
however, VPA treatment starting at the age of 9 mo could 
also signifi  cantly reduce neuritic plaque formation (  Fig. 1 A, 
c and d  ). The number of plaques in VPA-treated and control 
mice were 11.09   ±   0.92 and 25.60   ±   3.50, respectively (P   <   
0.005;   Fig. 1 E  ). The area of plaques was also signifi  cantly re-
duced in VPA-treated mice compared with control by 43.10   ±   
11.13% for the 7-mo-old group (P   <   0.01) and by 59.66   ±   
5.44% for the 9-mo-old group (P   <   0.05). In addition to re-
ducing neuritic plaque formation, VPA treatment also sig-
nifi  cantly increased microtubule-associated protein (MAP)-2 
immunoreactivity (  Fig. 1 C  ), which indicated a protective ef-
fect on dendritic damages and promoting neurite outgrowth in 
the transgenic mice. Similar results were obtained with silver 
staining (unpublished data). 
  To further confi  rm VPA  ’  s eff  ect on AD pathogenesis, 
APP23 transgenic mice were crossbred with PS45 transgenic 
mice to generate APP23/PS45 double-transgenic mice. PS45 
mice have an overexpression of the human familial AD-associ-
ated G384A mutant presenilin-1. The double-transgenic mice 
developed detectable neuritic plaques in the neocortex and 
hippocampus as early as 1 mo of age. Double-transgenic mice 
were treated with 30 mg/kg VPA at 6 wk of age for 4 wk. 
VPA treatment markedly inhibited neuritic plaque formation 
(  Fig. 1 A, f and d  ) and signifi  cantly reduced plaque numbers 
from 14.84   ±   1.67 to 2.862   ±   0.65 (P   <   0.0001;   Fig. 1 F  ). 
Thiofl  avin S staining also confi  rmed VPA-induced reduction 
of A    -containing neuritic plaque formation in the brains of 
APP23 single-transgenic (  Fig. 1 B, b and a  ) and APP23/PS45 
double-transgenic (  Fig. 1 B, d and c  ) mice. Over the 4-wk in-
jection period, VPA treatment did not aff  ect food and water 
consumption of the mice, and no signifi  cant weight changes 
were observed between the treatment and control groups (un-
published data). These data clearly demonstrate that VPA in-
hibits A     neuritic plaque formation in vivo. 
  VPA treatment signifi  cantly improves memory defi  cits 
in AD model mice 
  To investigate whether VPA treatment aff  ects learning and 
memory in AD pathogenesis, behavioral tests were performed 
after APP23 mice received 1 mo of VPA treatment starting at 
the age of 7 mo. The Morris water maze was used to deter-
mine the eff  ect of VPA on spatial memory. In the visible plat-
form tests, VPA-treated and control APP23 mice had similar 
escape latency (53.190   ±   1.56 and 49.75   ±   2.47 s; P   >   0.05; 
  Fig. 2 A  ) and path length (7.03   ±   1.33 and 6.78   ±   1.60 s; P   >   
0.05;   Fig. 2 B  ), which indicated that VPA treatment did not 
aff  ect mouse motility or vision.   In the hidden platform-swim-
ming test, APP23 mice treated with VPA showed signifi  cant 
improvements compared with the vehicle-treated controls. 
The escape latency on the third and fourth day of the hidden 
platform test was shorter (15.95   ±   1.61 and 12.80   ±   1.83 s) 
than nontreated APP23 mice (29.04   ±   2.99 and 24.89   ±   3.33 s; 
P   <   0.001;   Fig. 3 C  ).   The VPA-treated mice were able to 
  Valproic acid (VPA) is one of four fi  rst-line antiepileptic 
drugs being increasingly used in the treatment of bipolar disor-
der. Like other anticonvulsants, VPA inhibits sodium, potas-
sium, and calcium channel functions. Although its direct in 
vivo target has yet to be defi  nitively identifi  ed (  26  ), VPA may 
enhance     -aminobutyric acid transmission (  27  ). VPA has been 
found to activate extracellular signal-regulated kinase, a protein 
kinase known to regulate AP-1 function, and mediate neuro-
trophic responses (  28  ). VPA treatment could lead to a change 
in glycogen synthase kinase (GSK-3) and histone deacetylase 
(HDAC) activity (  29  ). Furthermore, VPA, like lithium, reg-
ulates the Wnt signaling pathway by increasing     -catenin ex-
pression (  30  ). Increased     -catenin expression is also seen after 
treatment with the chemically unrelated HDAC inhibitor 
trichostatin A. This mechanism may explain some eff  ects of 
VPA on gene expression and neurodevelopment (  31  ). It has 
been shown that increased histone acetylation by HDAC in-
hibitors facilitates synaptogenesis and improves learning and 
memory, suggesting that inhibition of HDAC may be a suit-
able therapeutic avenue for neurodegenerative diseases (  32  ). 
  In this study, we examined the eff  ects of VPA on AD 
neuropathology and behavioral defi  cits and identifi  ed its un-
derlying mechanism. We found that VPA inhibited GSK-
3      –  mediated     -secretase cleavage of APP both in vitro and 
in vivo. Furthermore, such inhibition decreased A     produc-
tion and neuritic plaque formation, as well as alleviated the 
memory defi  cits in AD transgenic model mice. Our data sug-
gest that VPA is eff  ective for antiamyloid therapy in the pre-
vention and treatment of AD. 
    RESULTS   
  VPA inhibits A     deposition and neuritic plaque formation 
in AD transgenic mice 
  To assess the eff  ect of VPA treatment on AD neuropathology, 
APP23 transgenic mice, which are an AD mouse model, were 
subjected to VPA treatment. APP23 mice carry the human 
Swedish mutant APP751 transgene driven by the neuronal-
specifi  c Thy1.2 promoter (Fig. S1, available at http://www
.jem.org/cgi/content/full/jem.20081588/DC1). APP23 mice 
develop amyloid plaques in the neocortex and hippocampus as 
early as 6 mo (  33  ). APP23 mice were treated with 30 mg/kg 
VPA at 7 mo of age, whereas age-matched control APP23 
mice received vehicle solution. To investigate whether VPA 
treatment could result in neuropathological changes in vivo, 
VPA-treated and control mice were killed after treatment and 
behavioral tests. 4G8 immunostaining and thiofl  avin S stain-
ing were used to detect A    -containing neuritic plaques in the 
brain (  Fig. 1, A and B  ).   Neuritic plaque formation was sig-
nifi  cantly decreased in APP23 mice treated with VPA (  Fig. 1 
A, b ), relative to controls (  Fig. 1 A, a  ). Quantifi  cation showed 
that overall VPA treatment reduced plaque number by     4-
fold (3.5   ±   0.79 vs. 14.95   ±   2.09 per slice; P   <   0.0001;   Fig. 
1 D  ). The eff  ects were similar among mice killed either im-
mediately, 1 mo, or 2 mo after treatment and behavioral test-
ing (0.75   ±   0.48 vs. 5.50   ±   1.32, P   <   0.001; 2.33   ±   0.50 vs. 
10.33   ±   1.26, P   <   0.001; and 5.30   ±   1.33 vs. 21.5   ±   02.76, JEM VOL. 205, November 24, 2008 
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0.01;   Fig. 2 D  ). In the probe trial on the last day of testing, the 
platform was removed. VPA treatment signifi  cantly improved 
the AD mouse  ’  s spatial memory. The number of times the 
swim signifi  cantly shorter distances to reach the platform (3.88   ±   
0.91 and 2.68   ±   1.02 m) compared with control mice (6.03   ±   
0.94 and 5.37   ±   1.38 m) on the third and fourth day (P   <   
  Figure 1.       VPA treatment signifi  cantly reduces neuritic plaque formation in AD transgenic mice.   (A) APP23 mice at the age of 7 or 9 mo and 
APP23/PS45 double-transgenic mice at the age of 6 wk were treated with 30 mg/kg VPA for 4 wk, whereas age-matched control APP23 mice received the 
vehicle solution. The mice were killed after behavioral tests and the brains were dissected, fi  xed, and sectioned. Neuritic plaques were detected using an 
A   -specifi  c monoclonal antibody 4G8 and the DAB method. The plaques were visualized by microscopy with 40X magnifi  cation. The number of neuritic 
plaques was signifi  cantly reduced in VPA-treated mice compared with controls. b, d, and f show the representative brain section of the 7-mo APP23 age 
group, 9-mo APP23 age group, and APP23/PS45 mice treated with VPA, and a, c, and e show their controls, respectively. Black arrows point to plaques. 
(B) Neuritic plaques were further confi  rmed using thiofl  avin S fl  uorescent staining and visualized by microscopy at 40X magnifi  cation. There were less 
neuritic plaques in VPA-treated mice (b and d) compared with age-matched control mice (a and c). a and b show brain sections of APP23 mice, and 
c and d show the brain sections of APP23/PS45 mice. White arrows point to green fl  uorescent neuritic plaques. (C) The brain sections of APP23 were 
also stained with MAP-2 antibody. VPA treatment signifi  cantly increased the number of MAP-2  –  positive neurites. Bars: (A and B) 400   μ  m; (C) 200   μ  m. 
(D) Quantifi  cation of neuritic plaques in APP23 mice with treatment starting at the age of 7 mo, the number represents mean   ±   SEM.   n   = 30 mice each. 
*, P   <   0.0001 by Student  ’  s   t   test. (E) Quantifi  cation of neuritic plaques in APP23 mice with treatment starting at the age of 9 mo, the number represents 
mean   ±   SEM.   n   = 12 mice each. *, P   <   0.005 by Student  ’  s   t   test. (F) Quantifi  cation of neuritic plaques in APP23/PS45 mice with treatment starting at the 
age of 6 wk, the number represents mean   ±   SEM.   n   = 25 mice for control and 29 mice for VPA. *, P   <   0.0001 by Student  ’  s   t   test.   2784   VPA INHIBITS ALZHEIMER’S DISEASE PATHOGENESIS   | Qing et al. 
latency and path length in the hidden platform trial of the 
Morris water maze test between the treatment and control 
groups (P   >   0.05). Although VPA treatment only slightly 
improved performance in the hidden platform tests in the 
APP23/PS45 double-transgenic mice, VPA treatment signif-
icantly improved performance in the probe trial (7.13   ±   0.70 
and 3.43   ±   1.13; P   <   0.05). 
mice traveled into the third quadrant, where the hidden plat-
form was previously placed, was significantly greater with 
VPA treatment compared with control (9.56   ±   2.62 and 4.18   ±   
1.06; P   <   0.005;   Fig. 2 E  ). These data indicate that VPA 
treatment signifi  cantly improves the memory defi  cits seen in 
APP23 mice. Because VPA treatment stopped a day before 
and there was no treatment during the behavioral testing, the 
eff  ect of VPA on the behavioral performance in the mice was 
not just acute, but also long lasting. 
  Behavioral tests were also performed on the older APP23 
mice administered with VPA at the age of 9 mo to assess their 
cognitive function. Despite a signifi  cant reduction in plaque 
formation, there were no signifi  cant diff  erences in the escape 
  Figure 2.       VPA improves memory defi  cits in AD transgenic mice.  
A Morris water maze test consists of 1 d of visible platform tests and 4 
d of hidden platform tests, plus a probe trial 24 h after the last hidden 
platform test. Animal movement was tracked and recorded by HVS 2020 
Plus image analyzer. The 7-mo APP23 age group mice were tested after 
1 mo of daily VPA (  n   = 30 mice) or vehicle solution (  n   = 30 mice) injec-
tions. (A) During the fi  rst day of visible platform tests, the VPA-treated 
and control APP23 mice exhibited a similar latency to escape onto the 
visible platform. P   >   0.05 by Student  ’  s   t   test. (B) The VPA-treated and 
control APP23 mice had similar swimming distances before escaping 
onto the visible platform in the visible platform test. P   >   0.05 by Stu-
dent ’ s   t   test. (C) In hidden platform tests, mice were trained with 6 trials 
per day for 4 d. VPA-treated APP23 mice showed a shorter latency to 
escape onto the hidden platform on the third and fourth day. P   <   0.001 
by ANOVA. (D) The VPA-treated APP23 mice had a shorter swimming 
length before escaping onto the hidden platform on the third and 
fourth day. P   <   0.01 by ANOVA. (E) In the probe trial on the sixth day, 
the VPA-treated APP23 mice traveled into the third quadrant, where the 
hidden platform was previously placed, signifi  cantly more times than 
controls. *, P   <   0.005 by Student  ’  s   t   test.   
  Figure 3.       VPA inhibits     -secretase cleavage of APP and A     pro-
duction.   (A) Half brains from VPA-treated and control APP23 mice of the 
7-mo age group were lysed in RIPA-Doc lysis buffer and separated with 
16% Tris-Tricine SDS-PAGE. APP full-length and CTFs (C99 and C83) were 
detected by C20 polyclonal antibody. PS1 was detected by anti-PS1 N-
terminal antibody 231. Total A     was isolated from the brain tissues with 
4G8 monoclonal antibody and detected using 6E10 anti-A     monoclonal 
antibody.     -Actin was detected by anti  –      -actin antibody AC-15 as the 
internal control. (B) Quantifi  cation showed that CTFs were signifi  cantly 
increased, whereas A     levels were markedly reduced in VPA-treated mice. 
  n   = 30 each for control and VPA group. *, P   <   0.05 by Student  ’  s   t   test. 
ELISA assay was performed to measure A    40 (C) and A    42 (D) levels in 
the conditioned media of primary neuronal cultures derived from the 
brain tissues of newborn APP23/PS45 mice. The cells were cultured for a 
week before VPA treatment for 24 h.   n   = 3. *, P   <   0.005 by Student  ’  s 
  t   test. (E) Swedish mutant APP stable cell line 20E2 was cultured and 
treated with different doses of VPA for 24 h, and cell lysates were sub-
jected to Western blot analysis. C99 and C83 were detected with C20 
antibody.     -Actin was detected by anti  –      -actin antibody AC-15 as the 
internal control. (F) Quantifi  cation of CTF (C99 and C83) generation in 
20E2 cells. VPA treatment signifi  cantly increased APP CTF production. 
  n   = 4. *, P   <   0.001 by ANOVA. (G) APP C99 stable cell line H99C1 was 
treated with different doses of VPA for 24 h, and the CTFs (C99, C89, and 
C83) were detected by 9E10 antibody.     -Actin was detected by anti  –     -actin 
antibody AC-15 as the internal control. (H) Quantifi  cation of CTFs (C99, 
C89, and C83) levels in H99C1 cells. VPA treatment signifi  cantly increased 
APP CTF production.   n   = 4. *, P   <   0.001 by ANOVA.     JEM VOL. 205, November 24, 2008 
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mice, likely by regulating APP processing through inhibition 
of     -secretase activity. To further investigate the underlying 
mechanism of VPA  ’  s eff  ect, we fi  rst examined its eff  ect on 
APP, BACE1, and PS1 gene expression. Our data show 
that VPA treatment did not change the mRNA levels of these 
genes (  Fig. 4, A  –  C  ).   Previous studies suggested that GSK-3     
regulated A     formation (  35  –  37  ). GSK-3     activity is regulated 
by its phosphorylation at the serine 9 (S  9  ) and tyrosine 216 sites 
(Y  216  ). The S  9   phosphorylation (pGSK-3      S9  ) inhibits GSK-3     
activity, whereas the Y  216   phosphorylation (pGSK-3      Y216  ) 
  VPA alters APP processing and inhibits A     production 
in vivo and in vitro 
  Our data clearly demonstrated that VPA treatment inhibited 
neuritic plaque formation and improved the memory defi  cits in 
the AD model mice. To investigate the underlying mechanism, 
we examined the eff  ect of VPA on APP processing. The level 
of APP C-terminal fragments (CTFs) and A     in the mouse 
brain tissues was assayed by Western blot analysis (  Fig. 3 A  ). 
VPA treatment signifi  cantly increased the levels of APP CTFs. 
The levels of     -secretase  –  generated C99 and     -secretase  –  gen-
erated C83 fragments were increased by 227.7   ±   36.8% in the 
brains of VPA-treated mice relative to controls (P   <   0.05;   Fig. 
3 B  ). Furthermore, the production of A     was signifi  cantly in-
hibited by VPA, and the total A     level was decreased to 18.71   ±   
6.24% in the brains of VPA-treated mice relative to controls 
(P   <   0.05;   Fig. 3 B  ). The A     ELISA assay was also performed to 
measure A      40   and A      42   levels in the transgenic brain tissues. 
The levels of A      40   and A      42   were reduced to 67.64   ±   2.89 and 
34.53   ±   1.53% in VPA-treated mice relative to controls, re-
spectively (P   <   0.05). To further confi  rm VPA  ’  s eff  ect on A     
production, we measured A      40   and A      42   levels in the condi-
tioned media of cultured primary cortical and hippocampal 
neurons derived from neonatal APP23/PS45 double-transgenic 
mice. VPA markedly reduced A     generation, decreasing A      40   
and A      42   levels to 48.86   ±   1.52 and 58.90   ±   3.43%, respec-
tively, relative to controls (P   <   0.005;   Fig. 3, C and D  ). VPA 
treatment had no signifi  cant eff  ect on APP and PS1 protein 
levels (  Fig. 3, A and B  ). The increased C99 and C83 levels, to-
gether with the decreased A     production in the brains of the 
VPA-treated transgenic mice, indicate that VPA inhibits     -
secretase cleavage of APP proteins. 
  To examine the eff  ect of VPA on APP processing in vi-
tro, 20E2 and H99C1 cells were treated with VPA. Consis-
tent with in vivo data from transgenic mouse models, VPA 
significantly increased APP C99 and C83 generation in 
20E2 cells, which are a HEK293 stable cell line overexpressing 
the Swedish mutant APP (  Fig. 3 E  ) (  34  ), and the levels of 
total CTFs were increased by 140.58   ±   5.5, 138.3   ±   5.58, 
176.7   ±   2.73, and 179.64   ±   4.10% with 0.5, 1.5, 5, and 
10 mM of VPA treatment, respectively (P   <   0.001;   Fig. 3 F  ). 
To further confirm the inhibitory effect of VPA on     -
secretase cleavage of APP, H99C1 cell line was established 
to stably overexpress APP C99, a major     -secretase cleav-
age product of APP (Fig. S3, available at http://www.jem
.org/cgi/content/full/jem.20081588/DC1). VPA treatment 
signifi  cantly increased the levels of APP CTFs, including 
C99, C89, and C83 (  Fig. 3 G  ). The levels of total CTFs 
were increased by 200.59   ±   4.10, 244.09   ±   3.87, 354.36   ±   
17.30, and 400.24   ±   17.63% with 0.5, 1.5, 5, and 10 mM 
of VPA treatment, respectively (P   <   0.001;   Fig. 3 H  ). These 
data clearly indicated that VPA inhibited     -secretase pro-
cessing of APP C99 protein. 
  VPA inhibits GSK-3 activity 
  Our data demonstrated that VPA signifi  cantly decreased A     
production and neuritic plaque formation in AD transgenic 
  Figure 4.       VPA inhibits GSK-3     activity.   Total RNA was isolated from 
N2a cells by TRI-Reagent (Sigma-Aldrich). A set of gene-specifi  c primers 
were used to amplify APP (A), BACE1 (B), and PS1 (C) genes.    -Actin  was 
used as an internal control. There was no difference in endogenous APP, 
PS1, or BACE1 mRNA levels between VPA-treated cells and controls. 
(D) Brain tissues from APP23/PS45 double-transgenic mice were sub-
jected to Western blot analysis to determine the levels of total GSK-3    
and  phospho – GSK-3   S9  . VPA increases phospho  –  GSK-3    S9   (P Ser9 )  levels, 
but not total GSK-3     levels in the transgenic mice. (E) N2a cells were 
treated with 5 mM of VPA for 0, 6, 12, and 24 h and lysed in RIPA-Doc 
buffer containing a series of serine and tyrosine phosphatase inhibitors. 
The cell lysates were subjected to Western blot analysis using a rabbit 
anti – phospho-GSK-3   Ser-9   antibody. Kodak Image Analysis software was 
used to quantify protein level.   n   = 3. *, P   <   0.001 by ANOVA. (F) Total GSK-
3     level was also measured. (G) Promoter assay. pTOPFLASH plasmid was 
cotransfected with pcDNA3-    -catenin and pcDNA3-Tcf expression plas-
mids into N2a cells. pCMV-Rluc was also cotransfected to normalize 
transfection effi  ciency. Luciferase assay was performed 48 h after trans-
fection. Promoter activity was indicated by the luciferase activity. VPA 
increased     -catenin-Tcf mediated transcription activation.   n   = 4. *, P   <   
0.005 by Student  ’  s   t   test.   2786   VPA INHIBITS ALZHEIMER’S DISEASE PATHOGENESIS   | Qing et al. 
developing axons but also increased axonal branching and 
formation of curved axons (  43  ). We show that VPA not only 
inhibits neuritic plaque formation but also promotes neurite 
outgrowth in the transgenic mice. 
  There have been VPA clinical trials conducted on AD 
patients. Profenno et al. reported that doses of   <  1,000 mg/d 
of divalproex sodium could be tolerated by patients in a 
Safety and Tolerability trial of 20 outpatients with probable 
AD (  44  ). In a clinical trial conducted on 14 moderate to se-
vere institutionalized AD patients with a mean age of 85.6 
yr that assessed VPA  ’  s eff  ect on agitation and aggression, 
VPA treatment was found to be ineff  ective for the manage-
ment of agitation and aggression (  45  ). These reports had 
little data that addressed VPA  ’  s eff  ect on AD pathogenesis, 
neuropathology, and cognitive impairments. Consistent 
with a previous work which showed that both lithium and 
VPA inhibited A     production in a Swedish mutant APP751 
stable cell line and PDAPP (APPV717F) transgenic mice 
(  37  ), we systematically demonstrated that in two diff  erent 
transgenic AD mouse models, VPA has signifi  cant benefi  -
cial eff  ects on AD pathogenesis. VPA reduced     -secretase 
cleavage of APP and A     production in vitro and in vivo, 
resulting in the prevention of AD-associated pathological 
outcomes. Furthermore, our data showed that early admin-
istration of VPA not only reduced neuritic plaque forma-
tion, but also rescued some memory defi  cits in AD transgenic 
mice. Meanwhile, we found that the inhibitory eff  ect of 
VPA on neuritic plaque formation was present up to 2 mo 
after discontinuing administration of VPA, indicating VPA  ’  s 
long lasting antiamyloid treatment potential for AD pa-
tients. However, when mice were treated with VPA at a later 
stage, when there was profound neuritic plaque formation, 
VPA could still reduce further neuritic plaque formation, 
albeit a lesser eff  ect on improving memory defi  cits in the 
older mice. Our preclinical animal study indicated that VPA 
can have eff  ects on neuropathology changes at early and late 
stages, but cognitive impairments can only be improved at 
an early stage intervention. These data suggest that VPA 
treatment should be applied at early stages of AD pathogen-
esis for eff  ective improvement of pathological and cognitive 
impairments. This information may also provide insights for 
VPA clinical trial designs. Our animal study suggests that 
the VPA trial might not show benefi  cial results on late or 
severe AD patients, whereas it might show signifi  cant im-
provements in early or mild AD patients. 
    MATERIALS AND METHODS   
  Transgenic mice and VPA treatment.     Animal experiment protocols 
were approved by The University of British Columbia Animal Care and 
Use committee. APP23 transgenic mice carry human APP751 cDNA with 
the Swedish double mutation at positions 670/671 (KM  →  NL) under con-
trol of the murine Thy-1.2 expression cassette (  33  ). PS45 transgenic mice 
carry human presenilin-1 cDNA with the M146V mutation. The geno-
type of the mice was confi  rmed by PCR using DNA from tail tissues. Mice 
were injected with 30 mg/kg VPA i.p. at the same time each day. Control 
mice were injected with PBS as a vehicle. We tabulated daily food and 
water consumption for each mouse. 
up-regulates GSK-3     activity. To examine whether GSK-3     
mediated VPA  ’  s eff  ect on APP processing in AD transgenic 
model mice, brain tissues of the double-transgenic mice were 
subjected to Western blot analysis for total GSK-3     and 
phospho-GSK-3     levels. We found no diff  erences in total 
GSK-3     protein levels between the VPA treatment and con-
trol mice groups; however, VPA treatment also signifi  cantly 
increased GSK-3      S9   levels in vivo (  Fig. 4 D  ). Consistent with 
the transgenic mouse data, VPA treatment in vitro also signifi  -
cantly facilitated the phosphorylation of GSK-3     at the S9 site. 
The level of phospho-GSK-3      S9   in VPA-treated N2a cells 
was increased to 147.87   ±   12.38 and 181.18   ±   16.55% after 
12- and 24-h treatment (P   <   0.001;   Fig. 4 E  ), whereas VPA 
had little eff  ect on total GSK-3     level in N2a cells (P   >   0.05; 
  Fig. 4 F  ). Further phosphorylation screening by the Kinet-
works 1.3 KPSS Phospho-site Profi  ling revealed that pGSK-
3      Y216   levels were markedly reduced by 37%. Collectively, 
these data suggest that VPA negatively regulates GSK-3     ac-
tivity. To examine the eff  ect of VPA on GSK-3      –  mediated 
biological function, we performed a     -catenin-Tcf reporter 
gene assay. Phosphorylated     -catenin by GSK-3 is rapidly de-
graded by the ubiquitin proteasome pathway, therefore inhibi-
tion of GSK-3 stabilizes     -catenin and activates downstream 
gene transcription. TOPFLASH, containing three copies of 
the optimal Tcf motif CCTTTGATC upstream of a minimal 
c  -Fos   promoter driving luciferase expression (  38  ), were co-
transfected with     -catenin and Tcf expression plasmids into 
N2a cells. VPA treatment signifi  cantly potentiated     -catenin  –
  mediated transcriptional activation, resulting in higher pro-
moter activity (138.80   ±   1.37%; P   <   0.005;   Fig. 4 G  ). The 
up-regulatory eff  ect of VPA was abolished when the cells were 
transfected with mutant     -catenin cDNA. Collectively, our 
data indicate that regulation of APP processing and neuritic 
plaque formation by VPA may be mediated by its eff  ect on the 
GSK-3     signaling pathway. 
    DISCUSSION   
  There has been no eff  ective method for the treatment or pre-
vention of AD. Inhibition of HDAC activity with pharma-
cological agents demonstrated limited levels of synaptogenesis 
and improved learning and memory (  32  ). Preclinical studies 
suggested that inhibition of A     production by altering APP 
processing at the     - or     -secretase site by lithium or nonste-
roidal antiinfl  ammatory drugs could potentially be avenues 
for AD drug development (  30, 39, 40  ). Here, we show that 
VPA, an antiepileptic drug, can serve as a highly eff  ective an-
tiamyloid treatment in AD transgenic model mice. VPA can 
inhibit GSK-3    , resulting in increased     -catenin protein lev-
els (  41, 42  ). GSK-3     is a key component of the Wnt signal-
ing pathway, controlling     -catenin levels and transcriptional 
responses required for development and cell growth. Consis-
tent with previous reports, we found that VPA inhibited 
GSK-3     activity by altering its phosphorylation state. VPA 
was also found to inhibit HDAC activity (  29  ), which could 
improve learning and memory (  32  ). Previous reports showed 
that VPA treatment not only induced synapsin I clustering in JEM VOL. 205, November 24, 2008 
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  RT-PCR.    RNA was isolated from cells using TRI-Reagent (Sigma-Aldrich). 
PowerScript reverse transcription (Invitrogen) was used to synthesize the 
fi  rst-strand cDNA from an equal amount of the RNA sample following the 
manufacturer  ’  s instruction. The newly synthesized cDNA templates were 
further amplifi  ed by Platinum   Tag   DNA polymerase (Invitrogen) in a 25-
  μ  l reaction. The following primers were used to specifi  cally amplify APP, 
PS1, and BACE1 genes: BACE1, forward 5    -ACCGACGAAGAGTCG-
GAGGAG-3     and reverse 5    -CACAATGCTCTTGTCATAG-3    ; APP, 
forward 5    -CGGAATTCCCTTGGTGTTCTTTGCAGAAG-3     and re-
verse 5    -CGGAATTCCGTTCTGCATCTCTCAAAG-3    ; PS1, forward 
5    -GGATCCGCCACCATGGTGTGGTTGGTGAATATGGC-3     and 
reverse 5    -CGGGATCCCTAGATATAAAATTGATGG-3    . 
      -Actin was used as an internal control. The samples were analyzed on a 
1.2% agarose gel. 
  Kinetwork KPSS 1.3 PhosphoSite analysis.     N2A cells were treated 
with 5 mM of VPA for 12 h, followed by homogenizing in lysis buff  er con-
taining 0.5% Triton X-100, 2 mM EGTA, 5 mM EDTA, 20 mM MOPS, 
200 mM sodium orthovanadate, 25 mM     -glycerophosphate, 20 mM 
sodium pyrophosphate, 30 mM sodium fluoride, 1 mM PMSF, and 1 
complete mini protease inhibitor cocktail tablet (Roche Diagnostics). 
The samples were diluted in 4  ×   SDS-sample buff  er to give a fi  nal protein 
concentration of 1   μ  g/  μ  l. The samples were then boiled and sent to Kinexus 
Bioinformatics Corp. for the Kinetworks KPSS 1.3 Phospho-Site multiim-
munoblotting analyses. The KPSS 1.3 screen tracks the phosphorylation 
levels of   >  35 protein kinases and their substrates. 
  A    40/42 ELISA assay.     Tissue extracts from transgenic mouse hippocampal 
and neocortical regions and conditioned cell culture media were collected. Pro-
tein inhibitors and AEBSF were added to prevent degradation of A     peptides. 
The concentration of A    40/42 was detected by     -amyloid 1  –  40 or 1  –  42 
Colorimetric ELISA kit (BioSource International, Inc.) according to the manu-
facturer  ’  s instructions. 
  Online supplemental material.     Fig. S1 shows the genotyping of the AD 
transgenic mice. Fig. S2 shows the results of VPA  ’  s eff  ect on plaque formation 
in diff  erent age groups of APP23 mice. Fig. S3 shows the generation of human 
APP C99 stable cell line H99C1. Online supplemental material is available at 
http://www.jem.org/cgi/content/full/jem.20081588/DC1. 
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